Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Income towards Parent Company: 2016-2024

Historic Income towards Parent Company for Dianthus Therapeutics (DNTH) over the last 7 years, with Dec 2024 value amounting to -$84.5 million.

  • Dianthus Therapeutics' Income towards Parent Company fell 43.90% to -$36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$125.5 million, marking a year-over-year decrease of 87.03%. This contributed to the annual value of -$84.5 million for FY2024, which is 94.65% down from last year.
  • As of FY2024, Dianthus Therapeutics' Income towards Parent Company stood at -$84.5 million, which was down 94.65% from -$43.4 million recorded in FY2023.
  • Dianthus Therapeutics' 5-year Income towards Parent Company high stood at -$28.6 million for FY2022, and its period low was -$84.5 million during FY2024.
  • Moreover, its 3-year median value for Income towards Parent Company was -$43.4 million (2023), whereas its average is -$52.2 million.
  • Data for Dianthus Therapeutics' Income towards Parent Company shows a maximum YoY tumbled of 94.65% (in 2024) over the last 5 years.
  • Over the past 3 years, Dianthus Therapeutics' Income towards Parent Company (Yearly) stood at -$28.6 million in 2022, then slumped by 52.00% to -$43.4 million in 2023, then plummeted by 94.65% to -$84.5 million in 2024.